The manufacturing facility of the company is located in the Sergiyev-Posad District of the Moscow Region. An integrated cycle manufacturing section is used to prepare injection solutions, fill ampoules, and further on pack, label and ship products to the warehouse. A manufacturing line used to produce genetically engineered medicine in pre-filled syringes was installed at the Sotex facility.The ampoule production capacity is up to 143 million ampoules, 13 million syringes per year. State-of-the-art equipment manufactured by major European concerns enables filling ampoules of 1, 2, 5, 10, and 20 milliliter capacity.
The facility is built and manufactures medicine in compliance with the requirements of the Good Manufacturing Practice (GMP) **. Equipment manufactured by major global companies was installed at the facility. Sotex conducts annual audits of its manufacturing capacity in coordination with foreign partners representing the leading global pharmaceutical companies.
The company manufacturing business is being developed in three directions:
1. Manufacturing and promotion of the own-brand medicine on the basis of the cutting-edge formulae that ensure high efficiency and safety.
2. Licensed manufacturing of brands and brand generics of the leading global companies (the line was launched in 2006 along with the Actovegin medicine licensed by Nycomed).
3. Manufacturing of the high-quality liquid INN generics.
The manufacturing line of the Group comprised more 150 medicines, including 115 positions of own-brand products in a variety of pharmaceutical forms as of the end of 12M-2018. Medicines used in cardiology, rheumatology, neurology, oncology, nephrology, as well as general purpose medicines make up the largest part of the manufacturing capacity Sotex’s partners within the joint manufacturing project are major foreign companies such as Sanofi, Nycomed, Takeda, Pierre Fabre, Bayer.
The Company’s regional service employed over 300 specialists.
*According to IQVIA. **Certified for GMP compliance by Nycomed (in relation to the licensed production of Actovegin)